Tecentriq (atezolizumab) ▼

Tecentriq is a cancer immunotherapy designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq is approved in countries around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various forms of non-small cell lung cancer (NSCLC), as well as certain types of small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), metastatic urothelial cancer (UC), PD-L1-positive metastatic triple-negative breast cancer (TNBC), BRAF V600 mutation-positive advanced melanoma and alveolar soft part sarcoma (ASPS).

Tecentriq is the first PD-(L)1 cancer immunotherapy which can be administered intravenously (into a vein) and subcutaneously (under the skin).